Clinical trials - Press Releases

Date	Title	Company
13-Dec-2022	1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors	1ST Biotherapeutics, Inc.
12-Dec-2022	Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma	Enterome
09-Dec-2022	Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid▼ showing statistically significant relative risk reduction in major adverse CV events1,2	Daiichi Sankyo UK
09-Dec-2022	Autolus announces FELIX trial of obe-cel meets its primary endpoint	Syncona Ltd
08-Dec-2022	iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289	iOnctura
08-Dec-2022	PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations	PHASTAR
08-Dec-2022	Almac Clinical Technologies announces IXRS®3 as market leading in key industry report	Almac
08-Dec-2022	Bloomsbury Genetic Therapies Announces CTA Filing for a Phase I/II Study for its Lead Gene Therapy Program	Bloomsbury Genetic Therapies
08-Dec-2022	The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis	UCB
08-Dec-2022	MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients	MetrioPharm AG
06-Dec-2022	Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials	Novotech Health Holdings Pte Ltd
06-Dec-2022	MHRA approves Adtralza®▼(tralokinumab) for the treatment of adolescent patients with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy	LEO Pharma
06-Dec-2022	Medidata Launches New myMedidata Native App to Expedite Study Start Up and Improve Patient Experience	Medidata
06-Dec-2022	Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022	Achilles Therapeutics
06-Dec-2022	Spago Nanomedical initiates clinical trial with SpagoPix in endometriosis and concludes SPAGOPIX-01	Spago Nanomedical
06-Dec-2022	Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials	Novotech
01-Dec-2022	The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency	mdgroup
28-Nov-2022	NUBEQA®▼ (darolutamide) + ADT in combination with docetaxel licenced by MHRA and made immediately available through NHS England early access deal for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC)	Health Unlimited
24-Nov-2022	SPRAVATO®▼ (esketamine) nasal spray data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1	Janssen Pharmaceutical Companies of Johnson & Johnson
23-Nov-2022	STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study	STORM Therapeutics